Trial Profile
SUSTRENIM Study – GIMEMA CML1415 Sustained treatment-free remission in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing Nilotinib versus Imatinib with switch to Nilotinib in absence of optimal response
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms SUSTRENIM
- 03 Jul 2018 New trial record